| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $2.7M | +115.2% |
| SG&A Expense | $5.3M | +115.2% |
| Operating Income | -$8.0M | -115.2% |
| Net Income | -$3.6M | +4.8% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $6.7M | +78.3% |
| Total Assets | $6.8M | +72.9% |
| Current Liabilities | $3.6M | +603.1% |
| Total Liabilities | $3.6M | +603.1% |
| Stockholders' Equity | $3.9M | +13.2% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$7.6M | -102.6% |
| Financing Cash Flow | $10.5M | +140.6% |